Cyclophosphamide for injection USP, 500 mg, 1 g and 2 g had annual US generic sales of approximately USD332m according to IQVIA for the 12 months ending April 2018.
Amneal is focused on developing, manufacturing and distributing generic, brand, and biosimilar products.
With approximately 6,500 employees in North America, Asia, and Europe, Amneal possesses an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.
Through its Impax specialty pharmaceutical division, focused principally on central nervous system disorders and parasitic infections, the company markets branded products.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling